Bayer Effort to Settle Roundup Cancer Cases Slowed By Covid-19
(Bloomberg) -- Bayer AG is blaming the spread of the coronavirus for slowing negotiations aimed at resolving lawsuits that claim its controversial Roundup weedkiller causes cancer and is asking consumers to settle for less, according to people familiar with the talks.
The German company recently backed out of tentative agreements to resolve the claims, said the people who asked not to be identified because the talks are private.
The move gives Bayer more time to assess the future impact of the pandemic on its business and may help it keep the total amount of Roundup settlements under $10 billion. Shareholders are pressuring management to resolve the litigation to lift the overhang on its shares.
Lagging revenues prompted company officials to ask consumers to take as much as 20% less in compensation than originally offered in the talks, the people said. That figure is going to be the focus of intense negotiations, they added.
Bayer officials confirmed Friday that requirements for people to practice social distancing to help slow the spread of the virus have gummed up the settlement process.
“Covid-19 dynamics, including restrictions imposed in recent weeks, have caused meeting cancellations and delayed this process,” Chris Loder, a U.S.-based Bayer spokesman, said in an emailed statement.
“We cannot speculate about potential outcomes from the negotiations or timing, given the uncertainties surrounding the pandemic and the confidentiality of this process, but we remain committed to engaging” in good-faith talks, Loder said.
The company is attempting to resolve more than 45,000 claims blaming exposure to glyphosate in Roundup -- made by Bayer's Monsanto Co. unit -- for non-Hodgkin's lymphoma in users of the product. The company denies glyphosate causes cancer.
But after losing three cancer trials in California that resulted in combined damages of $191 million, Bayer agreed to postpone the next round of Roundup trials to provide more time for negotiations. At least a half-dozen trials scheduled to start in the first quarter of this year have been put on hold. Bayer is appealing the verdicts.
Bayer shares fell under siege after the company acquired Monsanto in June 2018, losing as much as 47% of their value as trial losses mounted and new cases multiplied. The stock price began edging up again with the prospect of a settlement drawing closer.
What Bloomberg Intelligence Says
A settlement on Roundup litigation, potentially valued at more than $10 billion, remains key, though the mediation process could be slowed by Covid-19 disruption. Headwinds from the latter should be manageable from a fundamentals standpoint given Bayer's diversified structure, but concerns about long-term growth in pharma remain amid the ongoing recovery in consumer health that's been aided by brand divestments.
Michael Shah, BI Industry Analyst
For a full report click here
Over the last four months, Bayer reached draft settlement agreements with law firms across the U.S. representing Roundup cancer patients, but the accords hadn't been finalized, the people said.
Because Bayer officials planned to use some operating revenues to help fund the settlements, they came back to the negotiating tables to ask consumers to take less than was originally offered, the people said. Lawyers must now go back and persuade their clients to do that, the people added.
Tom Claps, a litigation analyst with Susquehanna Financial Group LLLP, said Friday that plaintiffs will likely accept lower compensation given the uncertainties created by the pandemic.
While it will be difficult to go back and ask for “massive discounts to the already agreed upon terms, Bayer has a strong argument that economic conditions have drastically changed requiring some discount,” Claps wrote in a note to clients.
Bayer isn't adverse to settling Roundup claims. Last month, the company agreed to pay $39.5 million to settle a proposed class-action case alleging its Monsanto unit ran misleading ads about the controversial Roundup weedkiller and its potential health risks to humans and animals.
Under the deal, Roundup's label won't say glyphosate -- the product's active ingredient -- only affects an enzyme found in plants. Consumers contend the chemical attacks an enzyme found in humans and some animals. The case didn't raise cancer claims.
The case is In re: Roundup Products Liability Litigation, MDL 2741, U.S. District Court, Northern District of California (San Francisco).
©2020 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.